Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|July 10, 2019
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled TrialRoy Fleischmann, Aileen L Pangan, In-Ho Song, et al.
Arthritis Research & Therapy|April 17, 2021
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trialsBernard Combe, Yannick Allanore, Rieke Alten, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Rheumatology (Oxford, England)|August 14, 2015
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritisGerd R Burmester, Patrick Durez, Galina Shestakova, et al.
Annals of the Rheumatic Diseases|August 24, 2012
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialPhilip G Conaghan, Patrick Durez, Rieke E Alten, et al.
Arthritis and Rheumatism|July 30, 2005
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trialJoel M Kremer, Maxime Dougados, Paul Emery, et al.
Arthritis Care & Research|May 20, 2014
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomesBhaskar Dasgupta, Bernard Combe, Ingrid Louw, et al.
Plos One|December 18, 2014
Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trialPatrick Durez, Pierre Vandepapeliere, Pedro Miranda, et al.
Clinical Rheumatology|August 6, 2018
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN studyDésirée van der Heijde, Patrick Durez, Georg Schett, et al.
ERJ Open Research|September 17, 2025
Lung involvement in rheumatoid arthritis, a prospective studyAntoine Froidure, Marie Perrot, Aleksandra Avramovska, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Arthritis & Rheumatology (Hoboken, N.J.)|July 10, 2019
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled TrialRoy Fleischmann, Aileen L Pangan, In-Ho Song, et al.
Arthritis Research & Therapy|April 17, 2021
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trialsBernard Combe, Yannick Allanore, Rieke Alten, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Rheumatology (Oxford, England)|August 14, 2015
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritisGerd R Burmester, Patrick Durez, Galina Shestakova, et al.
Annals of the Rheumatic Diseases|August 24, 2012
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialPhilip G Conaghan, Patrick Durez, Rieke E Alten, et al.
Arthritis and Rheumatism|July 30, 2005
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trialJoel M Kremer, Maxime Dougados, Paul Emery, et al.
Arthritis Care & Research|May 20, 2014
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomesBhaskar Dasgupta, Bernard Combe, Ingrid Louw, et al.
Plos One|December 18, 2014
Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trialPatrick Durez, Pierre Vandepapeliere, Pedro Miranda, et al.
Clinical Rheumatology|August 6, 2018
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN studyDésirée van der Heijde, Patrick Durez, Georg Schett, et al.
ERJ Open Research|September 17, 2025
Lung involvement in rheumatoid arthritis, a prospective studyAntoine Froidure, Marie Perrot, Aleksandra Avramovska, et al.
Pageof 12